VKTX Viking Therapeutics
Viking Therapeutics earnings company data as of 8:00 PM ET 10/22
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 28 Oct | EPS | 1.00 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by VKTX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $150K bought by 1 insider
- $2.7M sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Neil William Aubuchon Chief Commercial OfficerBuy$150K 4,475 shares at $33.50 New stakeTraded Mar 10 Filed Mar 10
-
Matthew W Foehr DirectorSale$562K 16,000 shares at $35.11 11% of stakeTraded Jan 2 Filed Jan 5
-
Charles A Rowland Jr. DirectorSale$2.1M 60,000 shares at $35.57 67% of stakeTraded Oct 27, 2025 Filed Oct 28, 2025
Also filed in the last 12 months, not counted as buying or selling: 21 stock grants, 18 sales to cover taxes, and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 21 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 1.01,2.03,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.